FairJourney Bio IL-12 Switch Antibody Study
Analysis based on 6 articles · First reported Aug 20, 2026 · Last updated Sep 01, 2026
The publication of this peer-reviewed study could enhance FairJourney Biologics's reputation as a leading antibody discovery partner, potentially attracting more clients and collaborations. It may also positively impact the venture-backed oncology program and the entities involved, though the approach has not yet been evaluated in vivo, so near-term market impact is limited.
FairJourney Biologics (FJBio), a global antibody discovery expert, announced the publication of a peer-reviewed study in mAbs describing a novel approach to improve the therapeutic window of IL-12, a potent anti-tumor cytokine. The study, titled 'Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate', reports the generation of a dual-specificity antigen-binding fragment (Fab) engineered to bind competitively to IL-12 and fibronectin-EDB (FN-EDB), a tumor-associated matrix antigen. This reversible switch masks IL-12 until it encounters FN-EDB, enabling conditional activation in the tumor microenvironment. The study describes the first demonstration of a reversible trans-activation logic gate for tumor-conditional cytokine delivery. In vitro data demonstrates FN-EDB-dependent IL-12 availability and activity, while quantitative systems pharmacology (QSP) modeling predicts a substantially improved therapeutic window. FJBio delivered the end-to-end antibody discovery and engineering campaign across its sites in Porto, Portugal, and Cambridge, UK. The study was conducted by researchers from Third Rock Ventures, IONTAS, Certara, and FJBio. Teresa Barata, Chief Scientific Officer and co-author, highlighted the potential of this approach in oncology.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard